Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY, a HUMIRA® biosimilar, available to patients

YUSIMRY (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company YUSIMRY will be available on for $569.27 plus dispensing and shipping fees DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) — Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs or Mark Cuban … Read more

FDA approves Yuflyma as Adalimumab\’s ninth biosimilar

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a highly concentrated citrate-free formulation, the manufacturer, Celltrion USA, announced today. It is the ninth biosimilar of adalimumab (Humira) to be approved in the United States. Yuflyma is approved for the treatment of adult patients with rheumatoid arthritis, psoriatic arthritis, ankylosing … Read more